Viewing Study NCT06590779



Ignite Creation Date: 2024-10-26 @ 3:39 PM
Last Modification Date: 2024-10-26 @ 3:39 PM
Study NCT ID: NCT06590779
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-26

Brief Title: Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Sponsor: None
Organization: None

Study Overview

Official Title: Evaluation of the Benefits of a Cosmetic Anti-hair Loss Lotion Applied in Combination With Finasteride in Male Subjects With Hair Loss Investigator-blinded Randomized Multi-center Study Performed Under Dermatological Control
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Androgenetic alopecia AGA also known as androgenic alopecia or male pattern baldness is the most common type of progressive hair loss AGA is a polygenetic condition with varying severity age of onset and scalp location of hair loss In men hair loss typically involves the temporal and vertex region while sparing the occipital region the characteristic horseshoe pattern Incidence and prevalence of AGA depend on age and race

Vichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone

The primary objective of this investigator-blinded randomized multi-center study is to quantitatively evaluate using the phototrichogram method the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None